5-ASA

Physicians’ Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohn’s Disease.

July 1, 2018July 1, 2018 ibdwatch

Physicians’ Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohn’s Disease. Dig Dis Sci. 2018 Jun 29;: Authors: Ma C, Ascoytia C, McCarrier KP, Martin M, Feagan BG, Jairath V Abstract BACKGROUND: Aminosalicylates are the most commonly prescribed therapy in Crohn’s disease (CD), despite uncertainty in the evidence to support their efficacy. AIMS: To examine physicians’ perspectives on aminosalicylate use for CD and explore the discordance between clinical practice and the evidence base. METHODS: A qualitative interview study was performed amongst physicians with at least 4 years…

Mesalazine-induced Bronchiolitis Obliterans with Organizing Pneumonia in a young patient with Ulcerative Colitis.

June 23, 2018June 23, 2018 ibdwatch

Related Articles Mesalazine-induced Bronchiolitis Obliterans with Organizing Pneumonia in a young patient with Ulcerative Colitis. J Crohns Colitis. 2018 Jun 20;: Authors: Costa JM, Carvalho SD, Soares JB PMID: 29931114 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29931114?dopt=Abstract

No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials.

June 22, 2018June 22, 2018 ibdwatch

Related Articles No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. Am J Gastroenterol. 2018 Jun 21;: Authors: Singh S, Proudfoot JA, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ Abstract OBJECTIVES: 5-aminosalicylates (5-ASA) are frequently continued in patients with moderate-severe ulcerative colitis (UC), even after escalation to biologic agents, without evaluation of the benefit of this approach. We conducted an individual participant data (IPD) pooled analysis of trials of infliximab and…

Systematic review and meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn’s disease.

June 1, 2018June 1, 2018 ibdwatch

Systematic review and meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn’s disease. Aliment Pharmacol Ther. 2018 May 30;: Authors: Ma C, Dutton SJ, Cipriano LE, Singh S, Parker CE, Nguyen TM, Guizzetti L, Gregor JC, Chande N, Hindryckx P, Feagan BG, Jairath V Abstract BACKGROUND: Aminosalicylates are the most frequently prescribed drugs for patients with Crohn’s disease (CD), yet evidence to support their efficacy as induction or maintenance therapy is controversial. AIMS: To quantify aminosalicylate use in CD clinical trials, identify factors associated with use and estimate…

Systematic review: safety of mesalazine in ulcerative colitis.

May 4, 2018 ibdwatch

Systematic review: safety of mesalazine in ulcerative colitis. Aliment Pharmacol Ther. 2018 May 03;: Authors: Sehgal P, Colombel JF, Aboubakr A, Narula N Abstract BACKGROUND: Mesalazine is the most commonly prescribed medication for mild to moderate ulcerative colitis. It is generally well tolerated with some reported side effects. AIM: To summarise adverse drug events to mesalazine and recommend techniques for management. Furthermore, to determine if there is a dose-dependent relationship between high (>2.4 g/day) vs low dosing (≤2.4 g/day) and occurrence of adverse drug events. METHODS: A literature search for relevant studies…

Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study.

January 24, 2018January 24, 2018 ibdwatch

Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study. Inflamm Bowel Dis. 2018 Jan 18;24(2):450-463 Authors: Yarlas A, D’Haens G, Willian MK, Teynor M Abstract Background: Disease activity of patients with ulcerative colitis (UC) predicts health-related quality of life (HRQL) and work-related outcomes (eg, absenteeism, productivity). We tested whether outcomes differed among patients in complete (clinical and endoscopic) remission, partial remission, or not in remission following treatment with multimatrix mesalamine. Methods:…

Mesalamine (5-ASA) for the prevention of recurrent diverticulitis.

October 4, 2017 ibdwatch

Mesalamine (5-ASA) for the prevention of recurrent diverticulitis. Cochrane Database Syst Rev. 2017 Oct 03;10:CD009839 Authors: Carter F, Alsayb M, Marshall JK, Yuan Y Abstract BACKGROUND: Diverticular disease is a common condition that increases in prevalence with age. Recent theories on the pathogenesis of diverticular inflammation have implicated chronic inflammation similar to that seen in ulcerative colitis. Mesalamine, or 5-aminosalicylic acid (5-ASA), is a mainstay of therapy for individuals with ulcerative colitis. Accordingly, 5-ASA has been studied for prevention of recurrent diverticulitis. OBJECTIVES: To evaluate the efficacy of mesalamine (5-ASA)…

Corrigendum: Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease.

September 30, 2017 ibdwatch

Corrigendum: Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. J Crohns Colitis. 2017 Aug 23;: Authors: PMID: 28962007 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/28962007?dopt=Abstract

The Use of 5-Aminosalicylic Acid in Children and Adolescents With Inflammatory Bowel Disease.

June 24, 2017June 24, 2017 ibdwatch

The Use of 5-Aminosalicylic Acid in Children and Adolescents With Inflammatory Bowel Disease. J Clin Gastroenterol. 2017 Jun 21;: Authors: Sokollik C, Fournier N, Rizzuti D, Braegger CP, Nydegger A, Schibli S, Spalinger J, Swiss IBD Cohort Study Group Abstract BACKGROUND: In ulcerative colitis (UC) 5-aminosalicylic acid (5-ASA) is recommended as primary therapy for mild to moderate disease. Topical 5-ASA has been proven especially effective. In Crohn’s disease (CD) the evidence for a beneficial role of 5-ASA is weak. We investigated the use of topical and systemic 5-ASA therapy in…

Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis.

June 2, 2017 ibdwatch

Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2017 Jun 01;: Authors: D’Haens GR, Sandborn WJ, Zou G, Stitt LW, Rutgeerts PJ, Gilgen D, Jairath V, Hindryckx P, Shackelton LM, Vandervoort MK, Parker CE, Muller C, Pai RK, Levchenko O, Marakhouski Y, Horynski M, Mikhailova E, Kharchenko N, Pimanov S, Feagan BG Abstract BACKGROUND: High concentration mesalazine formulations are more convenient than conventional low concentration formulations for the treatment of ulcerative colitis (UC). AIM: To compare the efficacy and…